Biontech and Pfizer have applied for accelerated registration of the vaccine against Covid-19

The German pharmaceutical company Biontech and its American partner Pfizer sent on Friday to the sanitary supervision of the quality of food and US medicines. An application for registration of its vaccine from coronavirus, reports TASS with reference to the BiionTech press release.

"We are sending our first request to the United States to register the Candidate vaccine against the Covid-19," the company from Minz on Twitter said. According to Spiegel, the application will be received by the American department on Friday. Earlier, US Azar, Minister of Health of the United States, reported on the receipt of receipt of the application on November 20.

"Filing an application for permission to use [the drug] in emergency situations in the United States is an important step towards making our Candidate vaccine available to the population of the whole world," said General Director and co -founder of Biontech Ugur Shakhin.

Pfizer and Biontech expect that if an American regulator approves an application, the drug can be used in emergency cases in December. The companies also began to send requests to the regulatory authorities in the EU and the UK

Earlier, both companies said that their vaccine offers 95 percent protection against Covid-19. As previously reported, a new drug belongs to a group of so -called gene vaccines containing genetic information about the causative agent. Biontech works mainly in the field of development of cancer immunotherapy methods.

The coronavirus vaccine, which is being developed by the American and German companies, will cost 15.5 euros per dose, previously reported on Friday Reuters with reference to the official representative of the EU. In a commentary for the agency, a representative of Pfizer said that they, together with Biontech, use a special formula for calculating price ranges depending on the volume and delivery time

The European Union can pay more than $ 10 billion for hundreds of millions of doses of vaccines from two manufacturers - Pfizer -Biontech and Curevac. In accordance with the transaction, the PFIZER and BIONTECH will receive from the European Union from 3.1 to 4.65 billion euros for 200 or 300 million doses of the vaccine.

The transaction includes compensation for the EU countries in case manufacturers decide to redirect their goods to the United States.